Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)—A Randomized Controlled Trial
Authors' conclusion
IF is a safe and feasible dietary option to ameliorate glycemic control while reducing total daily insulin dose and body weight in insulin-treated people with type 2 diabetes.
Study context
- Population
- People with insulin-treated T2D; dietary counseling and CGM providedrandomized
- Participants
- 46 people
- Comparison
- Intermittent fasting vs control
- Primary endpoint
- Coprimary: change in HbA1c from baseline; composite end point:
- Weight reduction ≥2%
- Insulin dose reduction ≥10%
- HbA1c reduction ≥3 mmol/mol
- Follow-up
- 12 weeks
Primary result
As reported in the abstract
Coprimary end points: HbA1c change; composite end point
| Group | Value | Composite end point achieved |
|---|---|---|
| Intermittent fasting (IF) | −7.3 ± 12.0 mmol/mol | 8 people |
| Control | 0.1 ± 6.1 mmol/mol | 0 |
Value
Intermittent fasting (IF)−7.3 ± 12.0 mmol/mol
Control0.1 ± 6.1 mmol/mol
Composite end point achieved
Intermittent fasting (IF)8 people
Control0
- IF vs Control: P = 0.012 — significant HbA1c reduction with IF
- IF vs Control: P < 0.001
Safety
- No severe hypoglycemia occurred
Original publication
Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)—A Randomized Controlled Trial. Diabetes Care. Published 12 December 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →